Teva

Executive Summary

Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical company with a dual business model, combining a leading generics and biosimilars platform with a growing innovative medicines division. Focused primarily on neuroscience and immunology, Teva serves millions of patients daily through a broad portfolio of generic and specialty medicines. The company has faced headwinds from generic pricing pressures and legal challenges, but has been actively reshaping its portfolio through pipeline advancement, cost optimization, and strategic biosimilar launches. Recent progress includes the development of key biosimilars and innovative therapies, positioning Teva for potential growth as it leverages its scale and expertise in complex generics and specialty pharmaceuticals.

Upcoming Catalysts (preview)

• Q1 2025Launch of Ustekinumab biosimilar (Simlandi) in the U.S.85% success
• Q2 2025TEV-48125 (fremanezumab) for prevention of migraine in adolescents label expansion decision70% success
• Q4 2025Phase 3 data readout for olanzapine LAI (TEV-48574) in schizophrenia60% success